{
  "meta": {
    "title": "Ischemic_Heart_Disease",
    "url": "https://brainandscalpel.vercel.app/ischemic-heart-disease-450382a2.html",
    "scrapedAt": "2025-11-29T18:33:45.721Z"
  },
  "questions": [
    {
      "id": 3619,
      "choices": [
        {
          "id": 14455,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Bradycardiac agent</span></span></span></p>"
        },
        {
          "id": 14456,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Rho kinase inhibition</span></span></span></p>"
        },
        {
          "id": 14457,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">K channel opener</span></span></span></p>"
        },
        {
          "id": 14458,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Inhibiting mitochondrial LC3- KAT</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trimetazidine is a drug approved for the treatment of angina pectoris. Its mechanism of action is assumed to be:</span></span></span></p>",
      "unique_key": "Q9218784",
      "question_audio": null,
      "question_video": null,
      "map_id": 36071,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Inhibiting mitochondrial LC3-KAT&nbsp;</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Trimetazidine</strong> works through <strong>non-hemodynamic mechanisms,</strong> meaning it <strong>does not</strong> affect the determinants of <strong>myocardial oxygen</strong> consumption such as <strong>heart rate (HR) and blood pressure (BP) at rest or during exercise. </strong>Despite this, it<strong> reduces the frequency of</strong> <strong>angina attacks </strong>and <strong>increases exercise capacity. Trimetazidine&#39;s </strong>mechanism of action is <strong>postulated to enhance cellular tolerance </strong>to <strong>ischemia </strong>by<strong> inhibiting mitochondrial long-chain 3-ketoacyl-CoA thiolase (LC3-KAT),</strong> a key enzyme in <strong>fatty acid oxidation.</strong> This <strong>inhibition </strong>results in a shift from <strong>fatty acid metabolism to increased glucose metabolism in the myocardium. </strong>Since fatty acid <strong>oxidation requires more oxygen to produce the same amount of ATP as glucose</strong>, the <strong>shift to glucose metabolism</strong> leads to <strong>reduced</strong> <strong>oxygen demand</strong>. <strong>Trimetazidine</strong> is often referred to as a <strong>partial fatty acid oxidation (pFOX) inhibitor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong>&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Incorrect</strong> because<strong> ivabradine&nbsp;is the bradycardiac agent </strong>used <strong>for angina</strong>, which <strong>acts by blocking the funny current in the SA</strong> <strong>node</strong>, not trimetazidine.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Incorrect</strong> as<strong> fasudil&nbsp;</strong>is the<strong> rho kinase inhibitor utilized for angina pectoris</strong>, not trimetazidine.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Incorrect </strong>because <strong>nicorandil&nbsp;is the K channel opener </strong>(which also has<strong> nitric oxide releasing properties</strong>) that is<strong> used for</strong> <strong>angina pectoris, </strong>rather than trimetazidine.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Trimetazidine</strong> is an <strong>antianginal medication</strong> that <strong>reduces the frequency of angina attacks</strong> and <strong>increases exercise capacity </strong>through a mechanism that likely involves the <strong>inhibition of mitochondrial LC3-KAT, </strong>leading to a shift from <strong>fatty acid to glucose metabolism</strong> in the<strong> myocardium and resulting</strong> in a<strong> reduced oxygen demand.</strong></span></span></span></p>",
      "correct_choice_id": 14458,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3633,
      "choices": [
        {
          "id": 14511,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It binds to the intracellular face of Na<sup>+</sup> K<sup>+</sup> ATPase enzyme</span></span></span></p>"
        },
        {
          "id": 14512,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">There is rise in intracellular Na<sup>+</sup></span></span></span></p>"
        },
        {
          "id": 14513,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It has positive ionotropic action</span></span></span></p>"
        },
        {
          "id": 14514,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inotropic action of digoxin is independent of cardiac innervation</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is not true about the mechanism of action of digitalis?</span></span></p>",
      "unique_key": "Q4426042",
      "question_audio": null,
      "question_video": null,
      "map_id": 36077,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) It binds to the intracellular face of Na+ K+ ATPase enzyme. </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Digitalis does not</strong> bind to the <strong>intracellular face of the Na+/K+ ATPase enzyme</strong>; instead, it <strong>binds</strong> to the <strong>extracellular face.</strong> The <strong>inhibition</strong> of this enzyme by <strong>digitalis causes a rise in intracellular sodium levels.</strong> As a consequence of <strong>increased intracellular sodium,</strong> the <strong>Na+/Ca2+ exchanger,</strong> which typically exports<strong> one calcium ion in exchange for three sodium ions,</strong> is <strong>inhibited</strong>. This leads to an <strong>increase in intracellular calcium levels</strong>. The elevated intracellular calcium enhances the <strong>contractility of the heart muscle</strong>, a mechanism known as<strong> positive inotropic action. </strong>Therefore, <strong>digitalis increases </strong>the <strong>force of cardiac contraction independently of</strong> <strong>cardiac innervation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. There is a rise in intracellular Na+:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement is<strong> true;</strong> the<strong> inhibition of Na+/K+ ATPase</strong> by <strong>digitalis</strong> leads to <strong>increased</strong> <strong>intracellular sodium.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:Calibri,sans-serif\"><strong>Option</strong>&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>C. It has positive inotropic action:</strong> This is<strong> true;</strong> digitalis <strong>increases the force of cardiac muscle contraction.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Inotropic action of digoxin is independent of cardiac innervation:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is also<strong> true;</strong> digitalis exerts its effects directly on the <strong>cardiac muscle cells, not </strong>through the<strong> nervous system.</strong> Though, it<strong> can decrease the AV conduction </strong>via<strong> vagus </strong>like action but this action is responsible for its<strong> use in atrial fibrillation</strong>,<strong> not as an inotropic drug.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Digitalis binds</strong> to the<strong> extracellular face of the Na+/K+ ATPase enzyme</strong>, leading to <strong>increased intracellular calcium,</strong> and in turn, <strong>positive inotropic action,</strong> which enhances<strong> cardiac contractility.</strong></span></span></span></p>",
      "correct_choice_id": 14511,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3617,
      "choices": [
        {
          "id": 14447,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Digoxin</span></span></span></p>"
        },
        {
          "id": 14448,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dobutamine</span></span></span></p>"
        },
        {
          "id": 14449,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amrinone</span></span></span></p>"
        },
        {
          "id": 14450,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metoprolol</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drug is used in CHF for relief of congestive symptoms and restoration of cardiac performance but does not possess inotropic action?</span></span></span></p>",
      "unique_key": "Q6890522",
      "question_audio": null,
      "question_video": null,
      "map_id": 36070,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Metoprolol&nbsp;</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Metoprolol, a beta-blocker,</strong> is used in the management of<strong> congestive heart failure (CHF)</strong> for the relief of <strong>congestive symptoms</strong> and <strong>restoration of cardiac performance</strong>, but it <strong>does no</strong>t have<strong> inotropic action</strong>. Instead, <strong>metoprolol</strong> works by <strong>blocking beta-adrenergic</strong> <strong>receptors in the heart,</strong> leading to a<strong> reduction in heart rate</strong>, <strong>decrease in cardiac workload, </strong>and <strong>improvement in cardiac efficiency</strong> over time. This mechanism helps in<strong> managing CHF without</strong> directly increasing the<strong> force of heart contractions.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Digoxin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Digoxin has a <strong>positive inotropic effect</strong>, <strong>increasing the force of cardiac contractions</strong>, and is used in<strong> CHF to improve</strong> <strong>symptoms and cardiac performance.</strong> It<strong> does not </strong>fit the criteria as it possesses <strong>inotropic action.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Dobutamine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Dobutamine is a <strong>beta-1 adrenergic agonist </strong>with <strong>positive inotropic effects</strong>, used primarily in <strong>acute heart</strong> <strong>failure</strong> to <strong>increase cardiac output. </strong>It directly <strong>increases the force of heart contractions.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Amrinone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Amrinone is a <strong>phosphodiesterase inhibitor</strong> with <strong>positive inotropic and vasodilatory effects</strong>, used to <strong>improve</strong> <strong>cardiac output </strong>in heart failure patients. Like <strong>dobutamine and digoxin,</strong> it <strong>increases the force of cardiac contractions.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the role of <strong>different classes of drugs</strong> in the management of <strong>CHF,</strong> particularly <strong>distinguishing</strong> those<strong> with and without inotropic action.</strong> <strong>Metoprolol&#39;s</strong> use in<strong> CHF illustrates</strong> the importance of managing <strong>heart rate and reducing</strong> <strong>myocardial oxygen demand</strong> as part of a strategy to <strong>improve cardiac performance</strong> <strong>without directly increasing the force of contraction</strong></span></span></span></p>",
      "correct_choice_id": 14450,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3795,
      "choices": [
        {
          "id": 15159,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nimodipine</span></span></span></p>"
        },
        {
          "id": 15160,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amlodipine</span></span></span></p>"
        },
        {
          "id": 15161,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diltiazem</span></span></span></p>"
        },
        {
          "id": 15162,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Verapamil</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs is used for reversal of cerebral vasospasm and infarct following subarachnoid hemorrhage? </span></span></span></p>",
      "unique_key": "Q9791712",
      "question_audio": null,
      "question_video": null,
      "map_id": 36078,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Nimodipine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Nimodipine </strong>is a <strong>cerebroselective calcium channel blocker </strong>with a particular affinity for <strong>cerebral blood vessels.</strong> Its use is indicated for the management of <strong>cerebral vasospasm</strong>, which is a complication that can follow <strong>subarachnoid hemorrhage. </strong>This vasospasm typically <strong>manifests 4-5 days after the hemorrhage</strong>, potentially leading to <strong>cerebral ischemia, infarction, and neurological deficits</strong>. <strong>Nimodipine&#39;s </strong>action of <strong>blocking calcium influx into vascular smooth muscle</strong> leads to the <strong>relaxation of these vessels,</strong> thereby <strong>mitigating vasospasm</strong> and<strong> reducing the risk of infarction </strong>and its associated <strong>morbidity and mortality</strong>. This action makes it a valuable agent in<strong> improving neurological </strong>outcomes following a <strong>subarachnoid hemorrhage.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Amlodipine:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While amlodipine is also a <strong>calcium channel blocker</strong>, it is not specifically indicated for<strong> cerebral vasospasm.</strong> It is more commonly used for<strong> hypertension and coronary artery disease.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Diltiazem:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Diltiazem is another <strong>calcium channel blocker</strong> with a <strong>broader cardiovascular effect profile </strong>and is <strong>not </strong>the drug of choice for<strong> cerebral vasospasm.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Verapamil:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Verapamil is a<strong> non-selective calcium channel blocker </strong>and is <strong>not</strong> specifically recommended for the treatment of <strong>cerebral vasospasm </strong>following <strong>subarachnoid hemorrhage.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Nimodipine</strong> is used for the<strong> reversal of cerebral vasospasm and reducing mortality</strong> after <strong>subarachnoid hemorrhage,</strong> due to its s<strong>elective action on cerebral blood vessels.</strong></span></span></span></p>",
      "correct_choice_id": 15159,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3823,
      "choices": [
        {
          "id": 15271,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Digoxin</span></span></span></p>"
        },
        {
          "id": 15272,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amiloride</span></span></span></p>"
        },
        {
          "id": 15273,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cimetidine</span></span></span></p>"
        },
        {
          "id": 15274,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ketoconazole</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following drugs can cause gynecomastia except:</span></span></span></p>",
      "unique_key": "Q1088630",
      "question_audio": null,
      "question_video": null,
      "map_id": 36076,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Amiloride</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Amiloride</strong> is a <strong>potassium-sparing diuretic</strong> that acts on the <strong>distal tubule of the nephron </strong>to <strong>inhibit sodium reabsorption</strong> and <strong>potassium excretion.</strong> It is<strong> not</strong> associated with the development <strong>of gynecomastia.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Digoxin:</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Digoxin,</strong> a <strong>cardiac glycoside,</strong> has been associated with <strong>gynecomastia</strong> as a rare<strong> adverse effect, </strong>possibly due to its <strong>estrogen-like effects and alterations in hormone metabolism.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Cimetidine:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cimetidine, a<strong> histamine H2 receptor antagonist</strong>, can cause <strong>gynecomastia </strong>by<strong> blocking androgen receptors </strong>and <strong>increasing prolactin secretion.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Ketoconazole:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ketoconazole, <strong>an antifungal agent, </strong>can <strong>inhibit testosterone synthesis </strong>by <strong>blocking cytochrome P450</strong> enzymes, leading to <strong>elevated estrogen levels </strong>and resulting in <strong>gynecomastia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to<strong> recognize medications associated with the development of gynecomastia a</strong>s an adverse effect.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">IMPORTANT DRUGS CAUSING GYNAECOMASTIA:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DI: DI</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">goxin</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">S: S</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">pironolactone</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C: C</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">imetidine, <strong>K</strong>etoconazole</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">O: O</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">estrogens</span></span></span></p>",
      "correct_choice_id": 15272,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3772,
      "choices": [
        {
          "id": 15067,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Spironolactone</span></span></span></p>"
        },
        {
          "id": 15068,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amiloride</span></span></span></p>"
        },
        {
          "id": 15069,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nicorandil</span></span></span></p>"
        },
        {
          "id": 15070,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Methyldopa</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs act as K channel opener? </span></span></span></p>",
      "unique_key": "Q9655821",
      "question_audio": null,
      "question_video": null,
      "map_id": 36081,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Nicorandil</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Nicorandil </strong>is recognized for its distinctive role as a <strong>potassium (K) channel opener. </strong>By activating these channels, nicorandil causes the <strong>hyperpolarization of vascular smooth muscle cells,</strong> which leads to the<strong> relaxation and vasodilation of both arterial and venous blood vessels</strong>. This vasodilatory effect contributes to a<strong> reduction in the myocardial oxygen demand and</strong> <strong>enhances the blood flow to</strong> <strong>areas</strong> of the<strong> heart muscle that are ischemic. </strong>The<strong> efficacy of nicorandil </strong>in the treatment of<strong> angina pectoris is not solely </strong>due to its <strong>potassium channel opening </strong>properties; it also possesses <strong>nitrate-like properties</strong> that further amplify its <strong>anti-anginal effects </strong>by <strong>reducing preload and afterload on the heart.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Spironolactone:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Spironolactone is a<strong> potassium-sparing diuretic</strong> that works <strong>at the level of the distal convoluted tubule</strong> in the kidneys but <strong>does not act </strong>as a<strong> K channel opener</strong> in the cardiovascular system.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Amiloride:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Amiloride is also a <strong>potassium-sparing diuretic</strong> that affects <strong>ion channels in the kidneys</strong>, but again, it <strong>does not</strong> <strong>open potassium channels </strong>in vascular smooth muscle.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Methyldopa:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Methyldopa is an <strong>antihypertensive medication</strong> that <strong>acts centrally as an alpha-2 agonist</strong> to<strong> lower blood</strong> <strong>pressure</strong>. It<strong> does not</strong> have<strong> K channel opening properties.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Nicorandil</strong> acts as a<strong> K channel opener and has nitrate-like properties, </strong>making it effective in the <strong>treatment of angina pectoris</strong> due to its ability to <strong>reduce myocardial oxygen demand </strong>and<strong> increase blood flow to the ischemic heart muscle.</strong></span></span></span></p>",
      "correct_choice_id": 15069,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3749,
      "choices": [
        {
          "id": 14975,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduce the dose of ACE inhibitor</span></span></span></p>"
        },
        {
          "id": 14976,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Add anti- tussive for treatment of cough</span></span></span></p>"
        },
        {
          "id": 14977,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Change to Angiotensin receptor blocker (ARB)</span></span></span></p>"
        },
        {
          "id": 14978,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Order for a CT scan of chest</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 56-year-old patient with essential hypertension on ACE inhibitors for 6 months developed chronic refractory dry cough. What would be the correct action to be taken?</span></span></span></p>",
      "unique_key": "Q4179287",
      "question_audio": null,
      "question_video": null,
      "map_id": 36073,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Change to Angiotensin receptor blocker (ARB)</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Angiotensin-converting enzyme (ACE) inhibitors </strong>are known to induce a <strong>dry cough </strong>in approximately<strong> 5&ndash;10% of patients</strong>. The mechanism behind this adverse effect is thought to be related to the <strong>accumulation of bradykinin</strong>, which is <strong>not broken down</strong> as efficiently due to the<strong> inhibition of ACE.</strong> This <strong>side effect </strong>occurs more frequently in <strong>women</strong> than men and is <strong>not dose-related</strong>, as it can develop anytime between<strong> 1 week and 6 months after starting the therapy. </strong>In some cases, the<strong> persistent cough requires the cessation</strong> of<strong> ACE inhibitor therapy. </strong>It has been noted that <strong>once ACE inhibitors</strong> are stopped, the cough usually resolves within 4 days. Alternative medications like<strong> ARBs do not inhibit </strong>the <strong>degradation of bradykinin </strong>and are thus <strong>not </strong>associated with the <strong>side effect </strong>of a <strong>dry cough,</strong> making them a <strong>suitable alternative for hypertension management in patients </strong>who develop a <strong>cough with ACE inhibitors.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Reduce the dose of ACE inhibitor:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Reducing the dose of the ACE inhibitor <strong>would not alleviate the cough </strong>since the adverse effect is not dose-related and the patient has already developed sensitivity to the drug.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Add anti-tussive for the treatment of cough:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> An anti-tussive <strong>would not</strong> address the underlying <strong>cause of the cough, </strong>which in this case is <strong>due to the ACE inhibitors.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Order for a CT scan of the chest:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A CT scan would be an <strong>unnecessary investigation </strong>and an additional cost burden for the patient, given that the cause of the <strong>chronic cough is already known to be drug-related </strong>and<strong> not indicative of an underlying</strong> <strong>pulmonary pathology.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">For a patient who develops a <strong>chronic dry cough while on ACE inhibitors, </strong>changing to an <strong>Angiotensin receptor blocker (ARB)</strong> is the <strong>correct course of action,</strong> a<strong>s ARBs do not </strong>cause this<strong> side effect.</strong></span></span></span></p>",
      "correct_choice_id": 14977,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3626,
      "choices": [
        {
          "id": 14483,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thyrotoxicosis</span></span></span></p>"
        },
        {
          "id": 14484,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Variant angina</span></span></span></p>"
        },
        {
          "id": 14485,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Migraine</span></span></span></p>"
        },
        {
          "id": 14486,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypertension</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propranolol can be used in all of the following conditions except.</span></span></span></p>",
      "unique_key": "Q7024934",
      "question_audio": null,
      "question_video": null,
      "map_id": 36075,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Variant angina&nbsp;</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Propranolol</strong> is <strong>contraindicated in variant angina (Prinzmetal&#39;s angina) </strong>because it is a<strong> non-selective beta-blocke</strong>r that can <strong>exacerbate</strong> <strong>symptoms. Variant angina </strong>is caused by <strong>coronary artery spasms,</strong> and<strong> beta-blockers </strong>like <strong>propranolol </strong>can<strong> increase the risk</strong> of these <strong>spasms</strong> by leaving <strong>unopposed alpha-mediated vasoconstriction</strong>, potentially worsening the condition.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Thyrotoxicosis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Propranolol</strong> is used in <strong>thyrotoxicosis</strong> to provide <strong>symptomatic relief</strong> from<strong> hyperthyroid symptoms </strong>such as <strong>tachycardia, anxiety, and tremors</strong>. It can also <strong>inhibit peripheral conversion of T4 to T3.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Migraine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Propranolol</strong> is used as a<strong> prophylactic treatment for migraine</strong>. It helps <strong>reduce the frequency </strong>and <strong>severity of</strong> <strong>migraine attacks.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Hypertension:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Propranolol </strong>can be used in the management of <strong>hypertension</strong>. It <strong>lowers blood pressure</strong> by <strong>reducing cardiac</strong> <strong>output</strong> and <strong>inhibiting</strong> <strong>renin</strong> release from the<strong> kidneys.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the <strong>therapeutic uses </strong>and <strong>contraindications of propranolol,</strong> a <strong>non-selective beta-blocke</strong>r. Recognizing that <strong>propranolol is contraindicated in variant angina </strong>due to its <strong>potential to worsen coronary artery spasms </strong>highlights the importance of considering the specific clinical context when selecting beta-blockers for treatment.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Indications of &beta;-Blockers:</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/88.jpg\" style=\"height:439px; width:1000px\" /></span></span></strong></p>",
      "correct_choice_id": 14484,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3780,
      "choices": [
        {
          "id": 15099,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amiodarone</span></span></span></p>"
        },
        {
          "id": 15100,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adenosine</span></span></span></p>"
        },
        {
          "id": 15101,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tenecteplase</span></span></span></p>"
        },
        {
          "id": 15102,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Verapamil</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55 yr. old male presented to emergency with severe acute chest pain, radiating to left shoulder and back in the last 20 minutes. It was associated with sweating. ECG is shown in the figure. Which of the following drug should be given to the patient?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/25/42.jpg\" style=\"height:243px; width:500px\" /></span></span></span></p>",
      "unique_key": "Q4556105",
      "question_audio": null,
      "question_video": null,
      "map_id": 36072,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Tenecteplase</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The description of the<strong> patient&#39;s symptoms</strong> along <strong>with the ECG (ST segment elevation in lead V1 to V5) </strong>makes the diagnosis of <strong>ST-segment elevation myocardial infarction (STEMI)</strong>. It would indicate the need for<strong> immediate reperfusion therapy. Tenecteplase </strong>is a <strong>fibrin-specific thrombolytic agent</strong> used in the management of <strong>STEMI </strong>to achieve <strong>reperfusion of the occluded coronary artery</strong>. It is given when <strong>primary percutaneous coronary intervention (PCI) </strong>is <strong>not </strong>available within the <strong>ideal time frame.</strong> <strong>Tenecteplase</strong> is <strong>administered </strong>to dissolve the<strong> thrombus</strong> that is<strong> blocking the coronary artery </strong>and causing the<strong> myocardial infarction.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Amiodarone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Amiodarone is an <strong>antiarrhythmic medication</strong> that is<strong> not </strong>indicated as an initial treatment for <strong>acute</strong> <strong>myocardial infarction</strong> unless there are accompanying<strong> life-threatening arrhythmias.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Adenosine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Adenosine is typically<strong> used </strong>in the treatment of certain forms of <strong>supraventricular tachycardia </strong>and <strong>not</strong> in the setting<strong> </strong>of<strong> acute myocardial infarction.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Verapamil:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Verapamil is a <strong>calcium channel blocker </strong>that is generally<strong> contraindicated</strong> in the setting of <strong>acute myocardial</strong> <strong>infarction,</strong> especially with evidence of<strong> STEMI,</strong> as it can further <strong>depress myocardial contractility</strong> and <strong>lead to hemodynamic</strong> <strong>deterioration.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The objective is to recognize the <strong>appropriate use of thrombolytic therapy</strong> in the treatment of<strong> STEMI when PCI is not immediately</strong> <strong>available.</strong> <strong>Prompt</strong> initiation of<strong> thrombolytic therapy</strong> can significantly<strong> improve outcomes in STEMI </strong>by restoring <strong>coronary blood flow</strong> and <strong>minimizing myocardial damage.</strong></span></span></span></p>",
      "correct_choice_id": 15101,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3844,
      "choices": [
        {
          "id": 15355,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rosuvastatin</span></span></span></p>"
        },
        {
          "id": 15356,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fenofibrate</span></span></span></p>"
        },
        {
          "id": 15357,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Evolocumab</span></span></span></p>"
        },
        {
          "id": 15358,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Niacin</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 52-year-old patient with a history of coronary artery disease and hyperlipidemia presents to the clinic for a routine follow-up. The patient is currently on atorvastatin for LDL cholesterol management but has recently had a lipid panel showing elevated Lipoprotein (a) levels. The patient is interested in exploring medication options that could specifically target the reduction of Lipoprotein (a) levels.&nbsp;Which of the following drugs is most likely to result in a reduction of Lipoprotein (a) levels?</span></span></span></p>",
      "unique_key": "Q1874354",
      "question_audio": null,
      "question_video": null,
      "map_id": 36074,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Niacin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Niacin, or Vitamin B3, </strong>has a distinctive role among <strong>lipid-lowering agents</strong> for its ability to significantly <strong>reduce Lipoprotein (a) levels.</strong> Although its precise mechanism of action in this context is<strong> not </strong>completely<strong> understood,</strong> <strong>niacin</strong> is believed to <strong>interfere with the</strong> <strong>synthesis and/or assembly of Lipoprotein (a) in the liver.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Rosuvastatin:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Statins</strong> like rosuvastatin are primarily known for<strong> their ability to lower LDL cholesterol </strong>but have a <strong>less</strong> pronounced effect on <strong>Lipoprotein (a).</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Fenofibrate:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Fenofibrate is used for its <strong>potent triglyceride-lowering effects </strong>and <strong>does not</strong> have a significant impact on <strong>Lipoprotein (a) levels.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Evolocumab:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Evolocumab, a<strong> PCSK9 inhibitor, </strong>primarily<strong> lowers LDL cholesterol </strong>and has a relatively <strong>mild effect on reducing</strong> <strong>Lipoprotein (a) levels </strong>compared to <strong>niacin.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Niacin is a lipid-lowering agent</strong> that can significantly <strong>reduce levels of Lipoprotein (a),</strong> distinguishing it from other<strong> lipid-modifying</strong> therapies that<strong> primarily focus on lowering LDL cholesterol or triglycerides.</strong></span></span></span></p>",
      "correct_choice_id": 15358,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3861,
      "choices": [
        {
          "id": 15423,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Class Ia</span></span></span></p>"
        },
        {
          "id": 15424,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Class Ib</span></span></span></p>"
        },
        {
          "id": 15425,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Class Ic</span></span></span></p>"
        },
        {
          "id": 15426,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Class II</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The anticonvulsant agent useful as an antiarrhythmic belongs to which class of antiarrhythmic drug?</span></span></span></p>",
      "unique_key": "Q1793602",
      "question_audio": null,
      "question_video": null,
      "map_id": 36079,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Class Ib</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phenytoin, classified as a <strong>Class Ib antiarrhythmic drug</strong>, exerts its<strong> antiarrhythmic effects</strong> by<strong> blocking sodium channels. </strong>This action helps<strong> stabilize cell membranes and reduce abnormal electrical activity</strong> in the <strong>heart,</strong> making it useful in the management of certain <strong>types of arrhythmias.</strong> While phenytoin is <strong>primarily used as an anticonvulsant </strong>to <strong>control seizure</strong>s, its <strong>sodium channel-blocking</strong> properties also make it effective in<strong> treating ventricular arrhythmias.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Class Ia antiarrhythmics:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Drugs in this class, <strong>such as quinidine and procainamide</strong>, <strong>block sodium channels</strong> and prolong the <strong>action potential duration</strong>. While effective in <strong>treating arrhythmias, </strong>they are<strong> not</strong> commonly used as <strong>anticonvulsants.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Class Ic antiarrhythmics:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> These drugs, <strong>including flecainide and propafenone,</strong> also<strong> block sodium channels </strong>but have <strong>minimal effects on action potential duration</strong>. They are primarily used for <strong>supraventricular arrhythmias</strong> and are <strong>not</strong> typically used as <strong>anticonvulsants.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Class II antiarrhythmics:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Class II drugs are <strong>beta-adrenergic blockers</strong>, such as<strong> propranolol and metoprolol,</strong> which <strong>reduce</strong> <strong>sympathetic stimulation of the heart</strong>. While they may have <strong>indirect effects on certain arrhythmias,</strong> they are<strong> not</strong> commonly used as <strong>anticonvulsants.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Understanding the <strong>classification of antiarrhythmic drugs</strong> and <strong>their mechanisms of action </strong>is crucial for <strong>selecting appropriate</strong> <strong>medications </strong>for the treatment of <strong>various arrhythmia</strong>s. Additionally, recognizing the <strong>dual utility of certain medications,</strong> like <strong>phenytoin, as both anticonvulsants and antiarrhythmics,</strong> enhances clinical decision-making in patients with overlapping conditions.</span></span></span></p>",
      "correct_choice_id": 15424,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3639,
      "choices": [
        {
          "id": 14535,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduced cardiac contractility</span></span></span></p>"
        },
        {
          "id": 14536,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased left ventricular end diastolic volume</span></span></span></p>"
        },
        {
          "id": 14537,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decreased diastolic perfusion pressure</span></span></span></p>"
        },
        {
          "id": 14538,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endothelium independent coronary vasodilatation</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient of Prinzmetal&rsquo;s angina is started on isosorbide mono nitrate. What is the mechanism of action of nitrates in this condition?</span></span></span></p>",
      "unique_key": "Q9854276",
      "question_audio": null,
      "question_video": null,
      "map_id": 36080,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Endothelium independent coronary vasodilatation</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Isosorbide mononitrate</strong>, when metabolized, <strong>releases nitric oxide (NO), </strong>which<strong> leads to the vasodilation of coronary arteries</strong>. This <strong>vasodilation is endothelium independent,</strong> meaning it<strong> does not</strong> rely on the <strong>endothelium cells of blood vessels to produce NO.</strong> <strong>Prinzmetal&#39;s (Variant/Vasospastic) angina</strong> is characterized by <strong>episodic angina </strong>due to <strong>coronary artery vasospasm,</strong> which<strong> temporarily</strong> <strong>reduces blood flow </strong>to the<strong> heart,</strong> producing <strong>ischemia and subsequent pain</strong>. The mechanism of action of nitrates, like <strong>isosorbide</strong> <strong>mononitrate, in Prinzmetal&rsquo;s angina</strong> involves the <strong>release of NO,</strong> which then <strong>binds to and activates guanylate cyclase</strong> in vascular smooth muscle cells. This activation <strong>leads to an increased level of intracellular cyclic guanosine monophosphate (cGMP)</strong>, which causes <strong>dephosphorylation of myosin light chain kinase (MLCK) </strong>and ultimately results in<strong> vascular smooth muscle relaxation </strong>and <strong>vasodilation of epicardial coronary arteries.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Reduced cardiac contractility:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong> as <strong>nitrates do not</strong> primarily act by <strong>reducing the contractility of the heart.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Increased left ventricular end diastolic volume:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong> because <strong>nitrates do not </strong>typically <strong>increase left ventricular end-diastolic volume;</strong> they<strong> reduce preload and afterload</strong> through <strong>vasodilation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Decreased diastolic perfusion pressure:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect </strong>as <strong>nitrates do not reduce diastolic perfusion pressure;</strong> their action is aimed at <strong>reducing vasospasm and increasing perfusion.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In<strong> Prinzmetal&rsquo;s angina,</strong> nitrates like<strong> isosorbide mononitrate </strong>work by<strong> causing endothelium independent coronary vasodilation, </strong>acting directly on the<strong> vascular smooth muscle through NO donation, </strong>which <strong>leads to pain relief </strong>by <strong>reversing the coronary vasospasm.</strong></span></span></span></p>",
      "correct_choice_id": 14538,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}